Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease

The advent of immune-checkpoint inhibitors targeting the programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis, both as monotherapy and in combination strategies, produced a paradigm change of the treatment algorithm for metastatic, non-oncogene addicted, non-small cell lung cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales: Passiglia, Francesco, Cetoretta, Valeria, De Filippis, Marco, Napoli, Valerio, Novello, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Immunotherapy in Other Thoracic Malignancies and Uncommon Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264339/
https://www.ncbi.nlm.nih.gov/pubmed/34295686
http://dx.doi.org/10.21037/tlcr-20-635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264339/
https://www.ncbi.nlm.nih.gov/pubmed/34295686
http://dx.doi.org/10.21037/tlcr-20-635

Ejemplares similares